Immunogenicity Assessment & Clinical Relevance

This year's Immunogenicity Assessment and Clinical Relevance conference brings the FDA together with leading industry and academic experts to discuss the development, application, and validation of immunogenicity assays to support clinical development. Learn how to manage drug and target interference and tolerance, understand the impact of pre-existing antibodies, and interpret the clinical significance of assay data. As well as traditional biologics, the meeting will also address novel modalities such as cell and gene therapies, RNA therapies, bispecifics, T cell engagers, multispecifics, fusion proteins, peptides, and antibody-drug conjugates (ADCs).